Everolimus + Octreotide LAR
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Polycystic Liver Disease
Conditions
Polycystic Liver Disease
Trial Timeline
Jun 1, 2010 → Jul 1, 2012
NCT ID
NCT01157858About Everolimus + Octreotide LAR
Everolimus + Octreotide LAR is a phase 2 stage product being developed by Novartis for Polycystic Liver Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01157858. Target conditions include Polycystic Liver Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01157858 | Phase 2 | Completed |
Competing Products
20 competing products in Polycystic Liver Disease